Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock in a transaction that occurred on Friday, January 10th. The shares were bought at an average cost of $12.51 per share, with a total value of $31,275.00. Following the transaction, the chief executive officer now owns 5,552,502 shares in the company, valued at $69,461,800.02. This represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $13.75 per share, for a total transaction of $24,750.00.
• On Thursday, January 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ GLSI opened at $12.06 on Wednesday. The firm’s 50 day moving average price is $13.08 and its 200-day moving average price is $14.01. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The company has a market cap of $158.53 million, a PE ratio of -15.07 and a beta of 1.66.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds have recently added to or reduced their stakes in GLSI. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences during the 3rd quarter valued at $253,000. Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences during the second quarter valued at $264,000. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences during the second quarter valued at $117,000. Barclays PLC increased its holdings in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.